CA2247025A1 - Antipathogenic peptides and compositions comprising them - Google Patents

Antipathogenic peptides and compositions comprising them Download PDF

Info

Publication number
CA2247025A1
CA2247025A1 CA002247025A CA2247025A CA2247025A1 CA 2247025 A1 CA2247025 A1 CA 2247025A1 CA 002247025 A CA002247025 A CA 002247025A CA 2247025 A CA2247025 A CA 2247025A CA 2247025 A1 CA2247025 A1 CA 2247025A1
Authority
CA
Canada
Prior art keywords
leu
lys
ile
peptide
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002247025A
Other languages
English (en)
French (fr)
Inventor
Yechiel Shai
Ziv Oren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2247025A1 publication Critical patent/CA2247025A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002247025A 1996-02-22 1997-02-20 Antipathogenic peptides and compositions comprising them Abandoned CA2247025A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL117223 1996-02-22
IL11722396A IL117223A0 (en) 1996-02-22 1996-02-22 Antipathogenic polypeptides and compositions comprising them

Publications (1)

Publication Number Publication Date
CA2247025A1 true CA2247025A1 (en) 1997-08-28

Family

ID=11068576

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247025A Abandoned CA2247025A1 (en) 1996-02-22 1997-02-20 Antipathogenic peptides and compositions comprising them

Country Status (13)

Country Link
US (1) US6172038B1 (https=)
EP (1) EP0904291A2 (https=)
JP (1) JP2000506128A (https=)
KR (2) KR19990087100A (https=)
CN (1) CN1216549A (https=)
AU (1) AU730069B2 (https=)
BR (1) BR9707691A (https=)
CA (1) CA2247025A1 (https=)
CZ (1) CZ264398A3 (https=)
EA (1) EA199800754A1 (https=)
IL (2) IL117223A0 (https=)
NZ (1) NZ331219A (https=)
WO (1) WO1997031019A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2281204A1 (en) * 1997-02-20 1998-08-27 Yeda Research And Development Co., Ltd. Antipathogenic synthetic peptides and compositions comprising them
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
PT1783222E (pt) 1998-10-23 2012-07-26 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
IL139720A0 (en) * 2000-11-16 2002-02-10 Yeda Res & Dev Diastereomeric peptides and pharmaceutical compositions comprising them
AU2004246909B2 (en) * 2003-06-19 2010-08-19 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
JP4849642B2 (ja) * 2004-11-24 2012-01-11 ネオプロ ラブス， エルエルシー 状態を処置するための方法および組成物
WO2006128289A1 (en) * 2005-06-02 2006-12-07 University Of Manitoba Use of brevinin-2r in the treatment of cancer
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007074457A2 (en) * 2005-12-27 2007-07-05 Yeda Research And Development Co. Ltd. Histidine-containing diastereomeric peptides and uses thereof
JP2009526046A (ja) * 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ 新規分子
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2014038004A1 (ja) * 2012-09-05 2014-03-13 株式会社メニコン 薬物徐放性眼用レンズ及びその製造方法
JP6093528B2 (ja) * 2012-09-19 2017-03-08 株式会社ミルボン スクリーニング方法
US11103547B2 (en) 2016-02-04 2021-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
GB2557654A (en) * 2016-12-14 2018-06-27 Uea Enterprises Ltd Method for nucleic acid depletion
CN113528600A (zh) * 2021-07-08 2021-10-22 石河子大学 一种利用沙门氏菌诱导蝇蛆制备抗菌肽的方法
CN119607173A (zh) * 2025-01-07 2025-03-14 天津医科大学朱宪彝纪念医院(天津医科大学代谢病医院、天津代谢病防治中心) 小分子肽lklkll在制备降血糖产品中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258454A (en) * 1988-09-01 1993-11-02 Riso National Laboratory Peptide synthesis method and solid support for use in the method

Also Published As

Publication number Publication date
WO1997031019A2 (en) 1997-08-28
NZ331219A (en) 2000-04-28
KR19990087100A (ko) 1999-12-15
IL125734A0 (en) 1999-04-11
AU1731997A (en) 1997-09-10
IL125734A (en) 2005-08-31
BR9707691A (pt) 1999-07-27
WO1997031019A3 (en) 1997-10-23
CN1216549A (zh) 1999-05-12
JP2000506128A (ja) 2000-05-23
KR20000071187A (ko) 2000-11-25
AU730069B2 (en) 2001-02-22
CZ264398A3 (cs) 1999-01-13
IL117223A0 (en) 1996-06-18
EA199800754A1 (ru) 1999-10-28
EP0904291A2 (en) 1999-03-31
US6172038B1 (en) 2001-01-09

Similar Documents

Publication Publication Date Title
US7001983B1 (en) Antipathogenic synthetic peptides and compositions comprising them
AU730069B2 (en) Antipathogenic peptides and compositions comprising them
Oren et al. Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure− function study
Oren et al. Cyclization of a cytolytic amphipathic α-helical peptide and its diastereomer: effect on structure, interaction with model membranes, and biological function
Ladram et al. Antimicrobial peptides from frog skin: biodiversity and therapeutic promises
Strahilevitz et al. Spectrum of antimicrobial activity and assembly of dermaseptin-b and its precursor form in phospholipid membranes
Hong et al. Structure and organization of hemolytic and nonhemolytic diastereomers of antimicrobial peptides in membranes
JP5335241B2 (ja) 抗微生物ヘキサペプチド
KR100891157B1 (ko) 짧은 생물활성 펩티드 및 그것들의 사용 방법
Shai Pardaxin: channel formation by a shark repellant peptide from fish
KR101345333B1 (ko) 라이신 및 트립토판 잔기가 ４번 반복된 신규한 항균 및 항진균 펩타이드 및 이의 용도
Ponnappan et al. Membrane-active peptides from marine organisms—antimicrobials, cell-penetrating peptides and peptide toxins: applications and prospects
Wood et al. Modified cysteine-deleted tachyplesin (CDT) analogs as linear antimicrobial peptides: Influence of chain length, positive charge, and hydrophobicity on antimicrobial and hemolytic activity
Park et al. Structure− activity relationships of piscidin 4, a piscine antimicrobial peptide
André et al. Structure–activity relationship-based optimization of small temporin-SHf analogs with potent antibacterial activity
Zhu et al. Antimicrobial and cytolytic activities and plausible mode of bactericidal action of the cell penetrating peptide penetratin and its Lys‐linked two‐stranded peptide
Saido-Sakanaka et al. Synthesis and characterization of bactericidal oligopeptides designed on the basis of an insect anti-bacterial peptide
Strøm et al. The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin
Kumari et al. A noncytotoxic temporin L analogue with in vivo antibacterial and antiendotoxin activities and a nonmembrane-lytic mode of action
Andrä et al. Shortened amoebapore analogs with enhanced antibacterial and cytolytic activity
KR100438416B1 (ko) Ｃａ－ｍａ 펩타이드의 아미노산 중 하나 또는 그 이상을치환하여 ＋ 전극과 소수성 영역이 증가된 신규한펩타이드 및 그를 포함하는 약학적 조성물
Kuhn-Nentwig et al. Cupiennin 1d*: the cytolytic activity depends on the hydrophobic N-terminus and is modulated by the polar C-terminus
Lim et al. The role of the central l-or d-Pro residue on structure and mode of action of a cell-selective α-helical IsCT-derived antimicrobial peptide
KR100935031B1 (ko) 헬리코박터 파일로리균의 리보좀 단백질 ｌ１유래의 유사체펩타이드로부터 풀림구조를 절단한 양이온 증가 항생펩타이드 및 항균 및 항진균용 조성물
MXPA99007799A (en) Antipathogenic synthetic peptides and compositions comprising them

Legal Events

Date Code Title Description
FZDE Discontinued